首页 | 本学科首页   官方微博 | 高级检索  
     


Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH
Affiliation:1. Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Apartado Postal 14-740, Mexico City, Mexico;2. Postgraduate Studies and Research Section, School of Higher Education in Medicine-IPN, Apartado Postal 11340, Plan de San Luis y Díaz Mirón s/n, Casco de Santo Tomás, Mexico City, Mexico;3. Laboratory of Neuroplasticity and Neurodegeneration, Department of Pharmacology, Cinvestav-IPN, Apartado Postal 14-740, Mexico City, Mexico;4. Department of Infectomics and Molecular Pathogenesis, Cinvestav-IPN, Apartado Postal 14-740, Mexico City, Mexico;5. Laboratory of Fibrosis and Cancer, Faculty of Medicine and Surgery. ‘Benito Juárez’ Autonomous University of Oaxaca, UABJO. Oaxaca, Mexico;6. National Council of Science and Technology CONACYT. Mexico City, Mexico;7. Laboratory of Liver Diseases; National Institute of Genomic Medicine, INMEGEN. Directorate of Catedras; National Council of Science and Technology, CONACYT. Mexico City, Mexico;8. Department of Cell Biology; Cinvestav-IPN, Apartado Postal 14-740, Mexico City, Mexico
Abstract:Introduction and objectivesAdministration of carbon tetrachloride (CCl4), along with an hepatopathogenic diet, is widely employed as a chemical inducer to replicate human nonalcoholic steatohepatitis (NASH) in rodents; however, the role of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome in this model remains unclear. We aimed to determine the relevance of NLRP3 inflammasome activation in the development of NASH induced by CCl4 along with an hepatopathogenic diet in male Wistar rats.Materials and methodsAnimals were fed either a high fat, sucrose, and cholesterol diet (HFSCD) or a HFSCD plus intraperitoneal injections of low doses of CCl4 (400 mg/kg) once a week for 15 weeks. Liver steatosis, inflammation, fibrosis, and NLRP3 inflammasome activation were evaluated using biochemical, histological, ultrastructural, and immunofluorescence analyses, western blotting, and immunohistochemistry.ResultsOur experimental model reproduced several aspects of the human NASH pathophysiology. NLRP3 inflammasome activation was induced by the combined effect of HFSCD plus CCl4 and significantly increased levels of both proinflammatory and profibrogenic cytokines and collagen deposition in the liver; thus, NASH severity was higher in the HFSCD+CCl4 group than that in the HFSCD group, to which CCl4 was not administered. Hepatic stellate cells, the most profibrogenic cells, were activated by HFSCD plus CCl4, as indicated by elevated levels of α-smooth muscle actin. Thus, activation of the NLRP3 inflammasome, triggered by low doses of CCl4, exacerbates the severity of NASH.ConclusionsOur results indicate that NLRP3 inflammasome activation plays a key role and may be an important therapeutic target for NASH treatment.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号